5.2 Wipe Sampling & Action Levels
Key Takeaways
- Wipe sampling verifies that engineering controls and cleaning practices are actually keeping HD residue off compounding surfaces; it must be performed initially at C-PEC/C-SEC setup and at least every 6 months thereafter
- Facilities typically test for marker hazardous drugs -- commonly cyclophosphamide, ifosfamide, and methotrexate -- rather than every HD compounded, since testing for all possible HDs is impractical
- USP <800> does not establish a specific numeric action level; each facility must determine its own acceptable contamination level and have a written plan for responding to exceedances
- An elevated wipe sample result should trigger recleaning, a root-cause investigation, review of engineering controls, and retesting to confirm remediation -- not just a reclean with no further action
Wipe Sampling & Action Levels
Cleaning and engineering controls can look effective on paper, but the only way to know whether hazardous drug (HD) residue is actually being kept off compounding surfaces is to test for it. Wipe sampling (also called surface wipe sampling or environmental wipe sampling) is the verification tool USP <800> requires, and it is a frequently tested topic within the 16%-weighted Facility Cleaning domain.
What Is Wipe Sampling?
Wipe sampling involves wiping a defined surface area -- typically the interior work surface of a C-PEC (BSC or CACI), the floor or counter of the C-SEC, and sometimes ancillary surfaces such as pass-through counters -- with a specialized wipe, then sending the wipe to a laboratory for analysis. The lab reports back a quantitative result (e.g., nanograms of drug per 100 cm²) showing whether, and how much, HD residue remains on that surface despite routine cleaning.
Marker Hazardous Drugs
It is not practical to test for every hazardous drug a facility compounds -- a busy oncology pharmacy may prepare dozens of different cytotoxic agents. Instead, facilities test for marker hazardous drugs: a small set of well-characterized, commonly compounded HDs with reliable, validated laboratory assays. The most widely used markers are:
- Cyclophosphamide
- Ifosfamide
- Methotrexate
A facility selects markers based on which HDs it actually compounds in meaningful volume; a result on these marker drugs is used as a proxy for overall HD contamination control, not proof that every other HD is absent from the surface.
When Wipe Sampling Is Required
| Trigger | Timing |
|---|---|
| Initial baseline | Upon initial setup of a new or relocated C-PEC/C-SEC |
| Routine/ongoing | At least every 6 months thereafter |
| Facility-specific | More frequently if the facility's Assessment of Risk or SOP calls for it |
Six months is the minimum frequency USP <800> requires -- a facility may test more often, but not less, unless it is following an approved alternative schedule under an Assessment of Risk for certain non-antineoplastic HDs.
The "Action Level" Exam Trap
A common exam trap is assuming USP <800> publishes a specific numeric action level -- a nanogram-per-square-centimeter threshold -- the way some agencies publish Permissible Exposure Limits for industrial chemicals. It does not. USP <800> requires the facility itself to determine what level of detected contamination is acceptable for its own program and to have a written plan for what happens when a wipe sample result exceeds that facility-determined level. There is no single number to memorize from USP <800> itself; the exam is testing whether you know a plan is required, not a specific numeric cutoff.
Responding to an Elevated Wipe Sample Result
When a wipe sample comes back above the facility's acceptable level, USP <800> expects a documented response, generally including:
- Reclean the affected surface(s) and area using the full four-step process (deactivation, decontamination, cleaning, and disinfection where applicable).
- Investigate the root cause -- was cleaning frequency inadequate, was technique poor, did PPE fail, or did an engineering control (e.g., BSC airflow, CACI containment) underperform?
- Reassess engineering controls and procedures in light of the finding, and correct any identified deficiency.
- Retest the surface to confirm the corrective action brought contamination back within the facility's acceptable range.
Simply recleaning without investigating why contamination was present in the first place does not satisfy USP <800>'s intent, and a technician who stops at "we recleaned it" has missed half the required response.
| Step | Action |
|---|---|
| 1 | Reclean using full four-step process |
| 2 | Investigate root cause |
| 3 | Reassess engineering controls/procedures |
| 4 | Retest to confirm remediation |
Documentation and Trending
Every wipe sample event -- whether the result is within the facility's acceptable range or not -- should be documented: the date, the surfaces tested, the marker HDs analyzed, the quantitative lab result, and (when applicable) the corrective actions taken. Facilities are expected to review these results over time rather than treating each sampling event in isolation. A single borderline result might reflect normal variability, but a marker HD that trends upward across consecutive sampling cycles at the same location is a stronger signal that cleaning frequency, technique, or an engineering control has degraded -- even if no single result technically exceeded the facility's acceptable level. Recognizing a trend, not just a single out-of-range number, is part of running an effective HD safety program and is the kind of judgment the PTCB exam expects candidates to apply to a described scenario.
Exam Scenario
A hospital's semiannual wipe sample from the CACI work surface comes back positive for methotrexate at a level the facility's own program defines as unacceptable. The correct first response is not to ignore the result because "no federal number was exceeded" -- it is to reclean the CACI using the full four-step process, investigate why residue was present (checking cleaning frequency logs, technique, and CACI containment performance), correct any deficiency found, and retest to confirm the surface is now within the facility's acceptable range.
Which of the following is commonly used as a marker hazardous drug in routine wipe sampling?
At minimum, how often does USP <800> require routine wipe sampling of C-PEC and C-SEC surfaces after the initial baseline testing?
Regarding numeric action levels for wipe sampling results, USP <800>:
A wipe sample from a CACI returns a cyclophosphamide result above the facility's acceptable level. After recleaning the surface, what should happen next?